Intellia Reports Positive Three-Year Follow-up...
CMN Clinical
Jun. 18, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Trobix Bio
Company type: Clinical
Main focus: Harnessing the human microbiome
Company stage: Pre-clinical
Diseases: side effects that result from treatment with checkpoint inhibitors, e.g, diarrhoea and colitis
Genome-editing tool: CRISPR
Funding stage: Series A Funding
Location: Netanya, Israel
Website: https://www.trobix.bio/company/
Ppeline: https://www.trobix.bio/pipeline/
Partners:
Israeli biotech company Trobix Bio is focusing on human microbiome research through its TBX™ technology platform, using CRISPR, phage, and synthetic biology to reprogramme targeted microbiome bacteria. Their pre-clinical programmes, TBX201 and TBX301, are being developed to alleviate severe diarrhoea and colitis, potentially enabling more oncology treatments and enhancing cancer patients' quality of life in markets exceeding $4 billion.
